Mpox Vaccine Capacity Expansion by Bavarian Nordic
Thursday, 12 September 2024, 01:33
Mpox Vaccine Capacity Expansion
Bavarian Nordic recently announced plans to enhance its mpox vaccine capacity, projecting an increase from a previous estimate of 10 million doses to a remarkable 13 million doses by the end of 2025.
Exploration of Production Options
In addition to the increased output forecast, Bavarian Nordic is actively exploring options to significantly expand its production capabilities. This initiative aims to bolster the availability of the mpox vaccine and meet rising global demands.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.